白血病细胞CD56抗原表达与急性髓系白血病患者预后的关系

doi:10.13481/j.1671-587x.20160218

吉林大学学报(医学版) ›› 2016, Vol. 42 ›› Issue (02): 283-289.doi: 10.13481/j.1671-587x.20160218

白血病细胞CD56抗原表达与急性髓系白血病患者预后的关系

李倩^1,2, 李劲高³, 周茂华⁴, 廖鹏军², 彭琪², 陈景⁵, 陈少贤⁵, 魏姗姗², 黄晖婷², 佘妙容²

1. 南方医科大学第二临床医学院内科, 广东广州 510515;
2. 广东省人民医院广东省医学科学院血液科, 广东广州 510080;
3. 中山大学孙逸仙纪念医院肾内科, 广东广州 510120;
4. 广东省人民医院广东省医学科学院检验科, 广东广州 510080;
5. 广东省人民医院广东省医学科学院病理生理研究室, 广东广州 510080

收稿日期:2015-09-24 发布日期:2016-03-31
通讯作者: 余妙容,主任医师,博士研究生导师(Tel:020-83827812-62121,E-mail:SMR807@163.com) E-mail:SMR807@163.com
作者简介:李倩(1989-),女,山西省运城市人,在读医学硕士,主要从事白血病干细胞方面的研究。
基金资助:
国家自然科学基金资助课题(81370664);广东省科技厅科技攻关计划项目资助课题(2013B921800188)

Relationship between CD56 antigen expression in leukemia cells and prognosis of patients with acute myeloid leukemia

LI Qian^1,2, LI Jingao³, ZHOU Maohua⁴, LIAO Pengjun², PENG Qi², CHEN Jing⁵, CHEN Shaoxian⁵, WEI Shanshan², HUANG Huiting², SHE Miaorong²

1. Department of Internal Medicine, Second Clinical Medical College, Southern Medical University, Guangzhou 510515, China;
2. Department of Hematology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China;
3. Department of Nephrology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China;
4. Department of Laboratory Medicine, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China;
5. Department of Pathophysiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China

Received:2015-09-24 Published:2016-03-31

摘要/Abstract

摘要：

目的: 探讨急性髓系白血病(AML)患者白血病细胞CD56抗原表达与预后的关系,阐明CD56抗原表达在预测AML患者预后中的作用。方法: 收集171例年龄14~60岁、采用去甲氧柔红霉素+阿糖胞苷(IA)方案首次诱导化疗的初治AML(AML-M3除外)患者的临床资料,流式细胞术检测白血病细胞CD56抗原的表达。采用COX回归模型分析患者生存时间的影响因素,采用双变量相关分析研究患者CD56阳性率与总生存时间(OS)间的关系。根据CD56抗原表达将患者分为CD56⁺组(n=52)和CD56^-组(n=119),同时根据CD56阳性表达率,以50%为界限,将CD56⁺组分为CD56阳性表达率≥50%组(n=39)和CD56阳性表达率<50%组(n=13),比较CD56⁺组和CD56^-组、CD56阳性表达率≥50%组和CD56阳性表达率<50%组患者完全缓解率(CRR)、复发率、中位OS、中位无病生存时间(DFS)和生存率。结果: CD56⁺组患者中位OS(14.2个月)低于CD56^-组(39.4个月)、CD56阳性表达率≥50%组患者中位OS(11.7个月)低于CD56阳性表达率<50%组(20.3个月),差异均有统计学意义(P<0.05)。CD56⁺组患者1年和2年生存率(61.5%、46.2%)低于CD56^-组(75.6%、63.9%)(P<0.05);CD56阳性表达率≥50%组患者1年生存率(53.8%)与CD56阳性表达率<50%组(84.6%)比较差异无统计学意义(P>0.05),但CD56阳性表达率≥50%组患者2年生存率(41.0%)明显低于CD56阳性表达率<50%组(61.5%)(P<0.05)。CD56⁺组患者CRR(63.5%)与CD56^-组(68.9%)以及CD56阳性表达率≥50%组(58.9%)与CD56阳性表达率<50%组(76.9%)比较,差异均无统计学意义(P>0.05)。CD56⁺组患者总复发率和1年内复发率(64.3%、37.5%)均高于CD56^-组(34.3%、17.9%)(P<0.05),而CD56阳性表达率≥50%组总复发率、1年内复发率(75.0%、42.9%)与CD56阳性表达率<50%组(37.5%、16.7%)比较,差异均无统计学意义(P>0.05);CD56⁺组患者中位DFS(12.7个月)低于CD56^-组(34.1个月)(P<0.05);CD56阳性表达率≥50%组与CD56阳性表达率<50%组中位DFS比较差异有统计学意义(P<0.05)。结论: 白血病细胞CD56抗原表达阳性是AML患者预后的不良因素,且阳性率越高,提示其预后越差。

关键词: 急性髓系白血病, CD56, 预后, 总生存时间, 无病生存时间

Abstract:

Objective: To investigate the expression of CD56 antigen in leukemia cells of the patients with acute myeloid leukemia (AML) and its relationship with the prognosis of AML, and to clarify the role of CD56 antigen expression in predicting the prognosis of the AML patients.Methods: 171 AML (non-M3) patients aged from 14 to 60 years old, who received a IA Regimen as the first time inducing chemotherapy were chosen.Flow cytometric analysis was used to evaluate the CD56 expression in leukemia cells.COX proportional regression analysis was used to select the prognostic factors, and bivariable analysis was used to study the relationship between the positive rate of CD56 and overall survival (OS).The CD56⁺ group(n=52), including CD56≥50% expression group(n=39) and CD56<50% expression group(n=13), and CD56^- group(n=119) were identified by the expression of CD56 antigen.The complete remission rate (CRR), the relapse rate, the median OS, the median disease-free survival (DFS) and the survival rate of patients were compared.Results: The medium OS of the patients in CD56⁺ group (14.2 months) was shorter than that in CD56^- group (39.4 months) (P<0.05).Moreover, the medium OS in CD56≥50% group was shorter than that in CD56<50% group (11.7 months vs 20.3 months, P<0.05).The 1-year and 2-year survival rates of the patients in CD56⁺ group(61.5%, 46.2%) were lower than those in CD56^- group(75.6%, 63.9%)(P<0.05).The 1-year survival rate had no significant difference between CD56≥50% group and CD56<50% group (53.8% vs 84.6%, P>0.05), while the 2-year survival rate in CD56≥50% group was lower than that in CD56<50% group (41.0% vs 61.5%, P<0.05).There were no significant differences of the CRR between CD56⁺ group(76.9%) and CD56^- group (68.9%) as well as CD56≥50% group(58.9%) and CD56<50% group(63.5%) (P>0.05). The relapse rate and first year relapse rate of patients in CD56⁺ group (64.3% and 37.5%) were significantly higher than those in CD56^- group (34.3% and 17.9%) (P<0.05).However, there were no significant differences of the relapse rate and first year relapse rate between CD56≥50% group(75.0% and 42.9%) and CD56<50% group(37.5% and 16.7%) (P>0.05).The DFS in CD56⁺ group was shorter than that in CD56^- group (P<0.05).The same DFS result was also found between CD56≥50% group and CD56<50% group(P<0.05).Conclusion: The expression of CD56 antigen in leukemia cells predicts a bad prognosis in the AML patients, and the higher expression of CD56 indicates the worse prognosis.

Key words: acute myeloid leukemia, CD56, prognosis, overall survival, disease-free survival

中图分类号:

R733.71

李倩, 李劲高, 周茂华, 廖鹏军, 彭琪, 陈景, 陈少贤, 魏姗姗, 黄晖婷, 佘妙容. 白血病细胞CD56抗原表达与急性髓系白血病患者预后的关系[J]. 吉林大学学报(医学版), 2016, 42(02): 283-289.

LI Qian, LI Jingao, ZHOU Maohua, LIAO Pengjun, PENG Qi, CHEN Jing, CHEN Shaoxian, WEI Shanshan, HUANG Huiting, SHE Miaorong. Relationship between CD56 antigen expression in leukemia cells and prognosis of patients with acute myeloid leukemia[J]. Journal of Jilin University Medicine Edition, 2016, 42(02): 283-289.

参考文献

[1] Dores GM,Devesa SS,Curtis RE,et al. Acute leukemia incidence and patient survival among children and adults in the United States,2001-2007[J].Blood,2012,119(1):34-43.

[2] Valgardsdottir R,Capitanio C, Texido G,et al.Direct involvement of CD56 in cytokine-induced killer-mediated lysis of CD56⁺ hematopoietic target cells[J].Exp Hematol,2014,42(12):1013-1021.

[3] Xu S,Li X,Zhang J,et al.Prognostic value of CD56 in patients with acute myeloid leukemia:a meta-analysis[J].J Cancer Res Clin Oncol,2015,141(10):1859-1870.

[4] 魏姗姗,周茂华,李劲高,等.急性髓系白血病患者白血病细胞CD34和CD38抗原的表达及其临床意义[J].吉林大学学报:医学版,2015,41(2):362-367.

[5] 张之南.血液病诊断及疗效标准[M].2版.北京:科学出版社,1998:168-218.

[6] Raspadori D,Damiani D, Lenoci M,et al.CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis[J].Leukemia,2001,15(8):1161-1164.

[7] Junca J,Garcia-Caro M,Granada I,et al.Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis[J].Ann Hematol,2014,93(9):1483-1489.

[8] Iriyama N,Hatta Y,Takeuchi J,et al.CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)[J].Leuk Res,2013,37(9):1021-1026.

[9] Ono T,Takeshita A,Kishimoto Y,et al.Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts[J].Cancer Sci,2014,105(1):97-104.

[10] Mason KD,Juneja SK,Szer J.The immunophenotype of acute myeloid leukemia:is there a relationship with prognosis[J].Blood Rev,2006,20(2):71-82.

[11] Alegretti AP,Bittar CM,Bittencourt R,et al.The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia[J].Rev Bras Hematol Hemoter,2011,33(3):202-206.

[12] Djunic I, Virijevic M,Djurasinovic V,et al.Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia[J].Med Oncol,2012,29(3):2077-2082.

[13] Chang H,Salma F,Yi QL,et al.Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia[J].Leuk Res,2004,28(1):43-48.

[14] Chang H,Brandwein J,Yi QL,et al.Extramedullary infiltrates of AML are associated with CD56 expression,11q23 abnormalities and inferior clinical outcome[J].Leuk Res,2004,28(10):1007-1011.

[15] Jekarl DW,Kim M,Lim J,et al.CD56 antigen expression and hemophagocytosis of leukemic cells in acute myeloid leukemia with t(16;21)(p11;q22)[J].Int J Hematol,2010,92(2):306-313.

[16] Benderra Z,Faussat AM,Sayada L,et al.Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias[J].Clin Cancer Res,2004,10(23):7896-7902.

[17] Montesinos P,Rayón C,Vellenga E,et al.Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens[J].Blood,2011,117(6):1799-1805.

白血病细胞CD56抗原表达与急性髓系白血病患者预后的关系

Relationship between CD56 antigen expression in leukemia cells and prognosis of patients with acute myeloid leukemia

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	朱广伟, 郑炜, 黄永建, 华进, 杨树钢, 叶建新. 髓样分化因子88在结直肠癌患者癌组织中的表达及其临床意义[J]. 吉林大学学报(医学版), 2018, 44(05): 1047-1051.
[2]	朱涛, 张国明, 严飞, 刘正, 霍强. 急性心肌梗死患者PCI术后心率变异性对主要不良心脏事件的评估价值[J]. 吉林大学学报(医学版), 2018, 44(04): 780-785.
[3]	高欢, 白元松, 代恩勇, 韩冷, 卢振霞, 赵亚男. 复发/难治性儿童B淋巴母细胞淋巴瘤1例报告及文献复习[J]. 吉林大学学报(医学版), 2018, 44(02): 416-420.
[4]	何欣, 杨婷婷, 高阳阳, 宋艳秋. 乳腺癌患者心理韧性及其心理干预方式的研究进展[J]. 吉林大学学报(医学版), 2018, 44(02): 455-460.
[5]	于云鹤, 杜烨, 韩冰, 李嗣杰, 宋乐连, 范志民. 新辅助化疗对Luminal B型乳腺癌各亚组的疗效观察及预后分析[J]. 吉林大学学报(医学版), 2018, 44(02): 356-362.
[6]	范励雯, 付彤, 古林, 吴迪, 贾泓瑶, 宋东. 副乳腺癌1例报告及文献复习[J]. 吉林大学学报(医学版), 2018, 44(02): 412-415.
[7]	孙慧颖, 杜波, 禹智, 刘洪泉, 于红. 突发性聋伴良性阵发性位置性眩晕病例分析并文献复习[J]. 吉林大学学报(医学版), 2017, 43(05): 1025-1029.
[8]	文思敏, 于多, 吕欣, 王铁君. 紫杉醇联合顺铂与单药顺铂2种同步放化疗方案对中晚期宫颈癌患者预后的影响及安全性评价[J]. 吉林大学学报(医学版), 2017, 43(05): 1002-1008.
[9]	苏军燕, 李迎今, 徐长妍. 急性白血病患儿白血病干细胞表面CD96和CD71的表达对其疗效和预后的影响[J]. 吉林大学学报(医学版), 2017, 43(04): 776-781.
[10]	杨冬阳, 赖晓嵘, 黎莹, 马立宇, 罗刚, 李子俊, 徐飞, 马冬. Ⅳ期结直肠癌轻微症状患者原发灶切除和KRAS基因突变对其预后的影响[J]. 吉林大学学报(医学版), 2017, 43(04): 805-811.
[11]	程诗佳, 王旭, 崔久嵬. 肿瘤患者异常铁代谢及其在肿瘤诊断和治疗中应用的研究进展[J]. 吉林大学学报(医学版), 2017, 43(01): 200-204.
[12]	郝铮, 刘楠, 王路, 李东原, 赵丛海, 刘伟明, 陈卓, 张金男. 立体定向与简易定位颅内置管治疗中等量高血压脑出血患者临床效果比较[J]. 吉林大学学报(医学版), 2017, 43(01): 130-134.
[13]	李杏杏, 谭婧瑾, 姜杉, 王珂. let-7和HMGA2在肺癌发生发展中作用的Meta分析[J]. 吉林大学学报(医学版), 2016, 42(06): 1116-1125.
[14]	谷三炜, 马红爽, 赵令, 姜振宇. 多发性肌炎/皮肌炎并发甲状腺相关疾病患者临床特征分析[J]. 吉林大学学报(医学版), 2016, 42(05): 999-1004.
[15]	丁显飞, 周学良, 豆萌萌, 李砺锋, 郭丽娜, 王峰, 樊青霞. 哺乳动物雷帕霉素靶蛋白的表达及其与乳腺癌预后关系的Meta分析[J]. 吉林大学学报(医学版), 2016, 42(04): 783-788.